Huang Johnny W, Famure Olusegun, Li Yanhong, Kim S Joseph
Division of Nephrology and the Kidney Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada;
Division of Nephrology and the Kidney Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; Division of Nephrology and the Renal Transplant Program, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada
J Am Soc Nephrol. 2016 Jun;27(6):1793-800. doi: 10.1681/ASN.2015040391. Epub 2015 Oct 8.
Several studies suggest a link between post-transplant hypomagnesemia and new-onset diabetes after transplantation (NODAT), but this relationship remains controversial. We conducted a retrospective cohort study of 948 nondiabetic kidney transplant recipients from January 1, 2000, to December 31, 2011, to examine the association between serum magnesium level and NODAT. Multivariable Cox proportional hazards models were fitted to evaluate the risk of NODAT as a function of baseline (at 1 month), time-varying (every 3 months), and rolling-average (i.e., mean for 3 months moving at 3-month intervals) serum magnesium levels while adjusting for potential confounders. A total of 182 NODAT events were observed over 2951.2 person-years of follow-up. Multivariable models showed an inverse relationship between baseline serum magnesium level and NODAT (hazard ratio [HR], 1.24 per 0.1 mmol/L decrease; 95% confidence interval [95% CI], 1.05 to 1.46; P=0.01). The association with the risk of NODAT persisted in conventional time-varying (HR, 1.32; 95% CI, 1.14 to 1.52; P<0.001) and rolling-average models (HR, 1.34; 95% CI, 1.13 to 1.57; P=0.001). Hypomagnesemia (serum magnesium <0.74 mmol/L) also significantly associated with increased risk of NODAT in baseline (HR, 1.58; 95% CI, 1.07 to 2.34; P=0.02), time-varying (HR, 1.78; 95% CI, 1.29 to 2.45; P<0.001), and rolling-average models (HR, 1.83; 95% CI, 1.30 to 2.57; P=0.001). Our results suggest that lower post-transplant serum magnesium level is an independent risk factor for NODAT in kidney transplant recipients. Interventions targeting serum magnesium to reduce the risk of NODAT should be evaluated.
多项研究表明,移植后低镁血症与移植后新发糖尿病(NODAT)之间存在关联,但这种关系仍存在争议。我们对948例非糖尿病肾移植受者进行了一项回顾性队列研究,研究时间为2000年1月1日至2011年12月31日,以探讨血清镁水平与NODAT之间的关联。采用多变量Cox比例风险模型评估NODAT风险,该风险是基线(1个月时)、随时间变化(每3个月)和滚动平均值(即每3个月移动一次的3个月平均值)血清镁水平的函数,同时对潜在混杂因素进行校正。在2951.2人年的随访期间,共观察到182例NODAT事件。多变量模型显示,基线血清镁水平与NODAT之间存在负相关(风险比[HR],每降低0.1 mmol/L为1.24;95%置信区间[95%CI],1.05至1.46;P=0.01)。在传统的随时间变化模型(HR,1.32;95%CI,1.14至1.52;P<0.001)和滚动平均模型(HR,1.34;95%CI,1.13至1.57;P=0.001)中,与NODAT风险的关联持续存在。低镁血症(血清镁<0.74 mmol/L)在基线(HR,1.58;95%CI,1.07至2.34;P=0.02)、随时间变化(HR,1.78;95%CI,1.29至2.45;P<0.001)和滚动平均模型(HR,1.83;95%CI,1.30至2.57;P=0.001)中也与NODAT风险增加显著相关。我们的结果表明,移植后血清镁水平较低是肾移植受者发生NODAT的独立危险因素。应评估针对血清镁以降低NODAT风险的干预措施。